Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,787 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Depression - Major Depressive Disorder Clear all
Completed No phase listed Observational

Genetic Study of Liver Enzymes in Patients With Side Effects From Antidepressants

NCT00360256
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Not applicable Interventional

A Study of the Cost Effectiveness of Generalist Care Managers for Depression Treatment in Medicaid Recipients

NCT00373477
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Generalist Care Manager vs Usual Care
Procedure
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
Asheville, North Carolina • Marshall, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2006 · Synced Oct 23, 2026, 8:46 AM EDT
Recruiting Not applicable Interventional

Causal Role of Delta-beta Coupling for Goal-directed Behavior in Anhedonic Depression

NCT06132581
View directory record Official record
Conditions
Major Depressive Disorder, Anhedonia
Interventions
Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4, Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4, Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4
Device
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder

NCT01052077
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
OPC-34712, Placebo, ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
43
States / cities
Birmingham, Alabama • Arcadia, California • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Phase 1 Interventional

Photobiomodulation to Alter Cerebral Blood Flow and to Affect the Emotional Status of Patients With Major Depression

NCT00961454
View directory record Official record
Conditions
Major Depression, Anxiety Disorder, Post-Traumatic Stress Disorder, Substance Abuse Disorder
Interventions
Photobiomodulation with a super-luminous light emitting diode
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2009 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Phase 2 Interventional Results available

Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)

NCT00731653
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Combination Product: BCI-024 + BCI-049
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Oct 23, 2026, 8:46 AM EDT
Terminated Phase 2 Interventional Results available

A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression

NCT04423757
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
BI 1358894, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Phase 1 Interventional

A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode

NCT07549581
View directory record Official record
Conditions
Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
Interventions
SEP-380135, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 23, 2026, 8:46 AM EDT
Recruiting Not applicable Interventional

In-patient SCC TMS

NCT05645575
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Open-label TMS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Not applicable Interventional

Understanding How Cognitive Remediation Works

NCT01683539
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Chronic Mental Disorder, Major Depression, Bipolar Disorder
Interventions
The Thinking Skills for Work Program, The Cognitive Skills for Work Program
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Phase 3 Interventional Results available

A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

NCT01187407
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
LY2216684, Placebo, SSRI
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chino, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 23, 2026, 8:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Psychological Development of Children of Parents With and Without Affective Disorders

NCT00001170
View directory record Official record
Conditions
Bipolar Disorder, Involutional Depression, Mood Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
1,045 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1979 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 8:46 AM EDT
Recruiting Not applicable Interventional

Telehealth Behavioral Activation for Teens

NCT06273995
View directory record Official record
Conditions
Depression, Suicide and Self-harm, Depression in Adolescence, Depression Mild, Depression Moderate, Depression Severe
Interventions
Behavioral Activation
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Not applicable Interventional Results available

Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients

NCT00151372
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Major Depression
Interventions
Treatment Adherence Intervention, Enhanced Care
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 95 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
3
States / cities
West Haverstraw, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2010 · Synced Oct 23, 2026, 8:46 AM EDT
Not listed Phase 4 Interventional

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

NCT02669030
View directory record Official record
Conditions
Depression, Major Depressive Disorder, MDD, Insomnia
Interventions
suvorexant, Placebo
Drug
Lead sponsor
Institute for Advanced Medical Research, Alpharetta, GA
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder

NCT05385783
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
CYB003, Psychotherapy, Placebo, Psychological Support
Drug · Behavioral
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
21 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Spinal Cord Stimulation for the Treatment of Major Depressive Disorder

NCT03433339
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active transcutaneous spinal direct current stimulation, Sham transcutaneous spinal direct current stimulation
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Phase 3 Interventional

Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features

NCT00610506
View directory record Official record
Conditions
Atypical Depression
Interventions
Escitalopram
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Not applicable Interventional

Lamotrigine Augmentation in Resistant Depression

NCT00901407
View directory record Official record
Conditions
Unipolar Depression
Interventions
lamotrigine, placebo, paroxetine
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated May 13, 2009 · Synced Oct 23, 2026, 8:46 AM EDT
Recruiting Phase 4 Interventional

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

NCT07105111
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Bryant, Arkansas • Chino, California • Fresno, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression

NCT00340379
View directory record Official record
Conditions
Affective Disorders
Interventions
Ziprasidone, Sertraline, Haloperidol
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2014 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Phase 3 Interventional

A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression

NCT00208156
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
13
States / cities
San Diego, California • Atlanta, Georgia • Las Vegas, Nevada + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Oct 23, 2026, 8:46 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study

NCT01944657
View directory record Official record
Conditions
1. Major Depressive Disorder
Interventions
Supplemental TMS, Standard Medication Monotherapy
Device · Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 23, 2026, 8:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Used With Treatment Resistant Depression in Older Adults

NCT02181231
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
venlafaxine XR, buprenorphine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 23, 2026, 8:46 AM EDT